|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hermes, Barbara; Schuette, Jochen; Cameron, Silke; Hohenberger, Peter; Jost, Philipp J.; Al-Batran, Salah-Eddin; Lindner, Lars H.; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Kallio, Raija; Jaakkola, Panu; Junnila, Jouni; Alvegard, Thor und Reichardt, Peter
(2020):
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
In: Jama Oncology, Bd. 6, Nr. 8: S. 1241-1246
Joensuu, Heikki; Wardelmann, Eva; Sihto, Harri; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hartmann, Jörg T.; Pink, Daniel; Cameron, Silke; Hohenberger, Peter; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Nilsson, Bengt; Kallio, Raija; Junnila, Jouni; Vehtari, Aki und Reichardt, Peter
(2017):
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial.
In: Jama Oncology, Bd. 3, Nr. 5: S. 602-609
Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby; Reichardt, Annette; Hartmann, Jörg T.; Pink, Daniel; Ramadori, Giuliano; Hohenberger, Peter; Al-Batran, Salah-Eddin; Schlemmer, Marcus; Bauer, Sebastian; Wardelmann, Eva; Nilsson, Bengt; Sihto, Harri; Bono, Petri; Kallio, Raija; Junnila, Jouni; Alvegård, Thor und Reichardt, Peter
(2016):
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
In: Journal of Clinical Oncology, Bd. 34, Nr. 3:
244-U99